CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6∗10 on Interindividual Variation in a Chinese Population-Reference-Cited by-同舟云学术

CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6∗10 on Interindividual Variation in a Chinese Population

Published:2017-05-02 Issue: Volume:8 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Chen Rui,Zheng Xin,Hu Pei

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference27 articles.

1. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).;Caudle;Genet. Med.,2017

2. Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.;Chen;Eur. J. Pharm. Sci.

3. Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine.;Chen;Int. J. Clin. Pharmacol. Ther.

4. In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma.;Chladek;Eur. J. Clin. Pharmacol.,2000

5. Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population.;Duché;Int. J. Clin. Pharmacol. Ther. Toxicol.,1993

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of cannabidiol-induced cytotoxicity in human hepatic cells;Toxicology;2024-08

2. Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships;Frontiers in Pharmacology;2024-03-22

3. Circulating Biomarkers Instead of Genotyping to Establish Metabolizer Phenotypes;Annual Review of Pharmacology and Toxicology;2024-01-23

4. Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients;BMC Psychiatry;2024-01-10

5. Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan;Frontiers in Pharmacology;2022-10-24